{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:28:23Z","timestamp":1761514103559,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.diabres.2017.11.004","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T16:20:09Z","timestamp":1510849209000},"page":"88-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Evaluation of protein C and protein S levels in patients with diabetes mellitus receiving therapy with statins and ACE inhibitors or angiotensin II receptor blockers"],"prefix":"10.1016","volume":"135","author":[{"given":"\u015eerife","family":"Akta\u015f","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sema","family":"U\u00e7ak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5467-5001","authenticated-orcid":false,"given":"Fatma","family":"Kurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Ta\u015fdemir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orkide","family":"Kutlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u0131nar","family":"Eker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2017.11.004_b0005","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1161\/01.CIR.0000088846.10655.E0","article-title":"The metabolic syndrome: more than the sum of its part?","author":"Reilly","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2017.11.004_b0010","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2337\/diaspect.21.3.160","article-title":"The pathopysiology of cardiovascular disease and diabetes: beyond blood pressure and lipids","volume":"21","author":"Dokken","year":"2008","journal-title":"Diabetes Spectrum"},{"key":"10.1016\/j.diabres.2017.11.004_b0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/CS20050025","article-title":"Vascular complication in diabetes mellitus: the role of endothelial dysfunction","volume":"109","author":"Schalkwijk","year":"2005","journal-title":"Clin Sci"},{"key":"10.1016\/j.diabres.2017.11.004_b0020","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1194\/jlr.R800059-JLR200","article-title":"Diabetes and atherosclerosis: is there a role for hyperglycemia?","volume":"50","author":"Chait","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.diabres.2017.11.004_b0025","unstructured":"Summary of Revision fort the clinical Practice Recommendations. Diabetes Care 2009."},{"issue":"3","key":"10.1016\/j.diabres.2017.11.004_b0030","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8727(01)00212-4","article-title":"Diabetes and macrovascular disease","volume":"16","author":"Vinik","year":"2002","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabres.2017.11.004_b0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1056-8727(00)00132-X","article-title":"Diabetes Mellitus: a hipercoagulable state","volume":"15","author":"Carr","year":"2001","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabres.2017.11.004_b0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jdiacomp.2014.01.006","article-title":"High coagulation factor levels and low protein C levels contribute to enhanced thrombin generation in patients with diabetes who do not have macrovascular complications","volume":"28","author":"Kim","year":"2014","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabres.2017.11.004_b0045","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s001250051352","article-title":"Coronary atherosclerosis in type II diabetes: anjiographic findings and clinical outcome","volume":"43","author":"Natali","year":"2000","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2017.11.004_b0050","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1161\/01.CIR.102.18.2180","article-title":"Coronary composition macrophage infiltration in atherectomy specimens from with diabetes mellitus","volume":"102","author":"Moreno","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2017.11.004_b0055","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1001\/archinte.161.14.1717","article-title":"The impact of diabetes mellitus on mortality from all causes and coronary heart disease in woman: 20 years of follow- up","volume":"161","author":"Hu","year":"2001","journal-title":"Arch Internal Medicine"},{"key":"10.1016\/j.diabres.2017.11.004_b0060","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/PL00002934","article-title":"Mortality and causes of death in the WHO multinational study of vascular disease in diabetes","volume":"4","author":"Morrish","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2017.11.004_b0065","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000081919","article-title":"Coagulat\u0131on and fibrinolisis parameters in type 2 diabetic patients with and without diabetic vascular complications","volume":"14","author":"Erem","year":"2005","journal-title":"Medical Principles and Practice"},{"issue":"4","key":"10.1016\/j.diabres.2017.11.004_b0070","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.dsx.2016.06.015","article-title":"The relation of prote\u0131n C and prote\u0131n S levels with cardiovascular risk in patients with diabetic neuropathy","volume":"10","author":"Akta\u015f","year":"2016","journal-title":"Diabetes Metabolic Syndrome: Clin Res Rev"},{"key":"10.1016\/j.diabres.2017.11.004_b0075","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019(CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL- cholesterol: a meta- analysis of data from 170000 participants in 26 randomised trials. Lancet vol. 376;2010: p. 1670\u201381.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"10.1016\/j.diabres.2017.11.004_b0080","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/j.amjcard.2012.04.002","article-title":"Management of cardiovascular risk: the importance of meeting lipid targets","volume":"110","author":"Gotto","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabres.2017.11.004_b0085","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/hq1101.098486","article-title":"Pleiotropic effects of 3-hydroxy- 3- methylglutaryl coenzyme A reductase inhibitors","volume":"21","author":"Takemoto","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabres.2017.11.004_b0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.amjcard.2005.06.009","article-title":"Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low- density lipoprotein cholesterol","volume":"96","author":"Liao","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabres.2017.11.004_b0095","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2174\/138161209787315684","article-title":"Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy","volume":"15","author":"Zhou","year":"2009","journal-title":"Curr Pharm Des"},{"issue":"251\u201325","key":"10.1016\/j.diabres.2017.11.004_b0100","first-page":"7","article-title":"Statins as antithrombotic drugs","volume":"127","author":"Violi","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2017.11.004_b0105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/01.ATV.0000151647.14923.ec","article-title":"Statins and blood coagulat\u0131on","volume":"25","author":"Undas","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabres.2017.11.004_b0110","first-page":"392","article-title":"Anticoagulant effect of statins and their clinical implications","volume":"111","author":"Undas","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.diabres.2017.11.004_b0115","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2337\/diacare.27.2.468","article-title":"Anti-inflammatory and anticoagulant effect of pravastatin in patients with type 2","volume":"27","author":"Sommeijer","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2017.11.004_b0120","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/jth.12223","article-title":"Statin therapy and levels of haemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis","volume":"11","author":"Adams","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.diabres.2017.11.004_b0125","first-page":"55","article-title":"Value of pleiotropic effects of angiotensin- converting enzyme inhibitors","volume":"50","author":"Zagidulin","year":"2010","journal-title":"Kardiologiia"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716318290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716318290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:06:51Z","timestamp":1759172811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822716318290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":25,"alternative-id":["S0168822716318290"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2017.11.004","relation":{},"ISSN":["0168-8227"],"issn-type":[{"type":"print","value":"0168-8227"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of protein C and protein S levels in patients with diabetes mellitus receiving therapy with statins and ACE inhibitors or angiotensin II receptor blockers","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2017.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}